Postpartum Hemorrhage Clinical Trial
Official title:
Impact of Balanced Crystalloids in Obstetric Hemorrhage: A Prospective Cohort Study
Introduction:
Obstetric hemorrhage is the most feared complication that can occur during childbirth and
continues to be the leading cause of death in pregnant women worldwide, about 7 women die
every hour in the world. This is defined as an accumulated loss of blood of more than 1000 mL
with signs and symptoms of hypovolemia within 24 hours of the birth process. The main
objective of resuscitation in these patients is precisely to reduce the deleterious effects
that are generated from the depletion of volume and the altered capacity of oxygen transport.
The current debate focuses on the safety and efficacy of each particular liquid during
resuscitation and on improving long-term patient outcomes. At present, there is no conclusive
evidence on the impact at the level of acid-base status, hydroelectrolytic balance and
potential kidney injury with respect to the use of balanced solutions such as Plasma-Lyte or
Ringer's Lactate.
Objective:
To determine the differences in the volume of liquids and blood products required with the
use of balanced crystalloids (Ringer's Lactate or Plasma-Lyte) in patients with obstetric
hemorrhage in the Hospital Universitario Fundación Santa Fe de Bogotá during 2018 - 2019.
Design, Materials, and methods:
Historical cohort analytical study. All patients over 18 years of age who present an
obstetric hemorrhage defined as bleeding> 1000 mL or less associated with signs or symptoms
of hemodynamic instability will be included. The most important exclusion criterion is the
presence of active infection at the time of the event. Patients will be divided into two
groups, those who underwent hydroelectrolytic resuscitation with Plasma-Lyte and Ringer
Lactate.
Results and conclusions With this study, we intend to describe the differences in the base
acid status measured by arterial gases in patients with obstetric hemorrhage. The aim is to
find a relationship between the different groups with clinical outcomes, such as days of ICU
stay and hospitalization, blood transfusion requirement, electrolyte disorders, acute kidney
injury and survival.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | July 30, 2020 |
Est. primary completion date | May 30, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patient with a diagnosis of obstetric hemorrhage (> 1000 mL). Over 18 years. Exclusion Criteria: - Patients with incomplete clinical history. - Patients with active infections. - Patients with a history of blood dyscrasias. - Patients with known kidney disease. - Patient with previous alteration of the acid-base status. |
Country | Name | City | State |
---|---|---|---|
Colombia | Hospital Universitario Fundación Santa Fe de Bogotá | Bogotá |
Lead Sponsor | Collaborator |
---|---|
Fundación Santa Fe de Bogota |
Colombia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Differences in the use of fluids and blood products | Differences in the use of fluids and blood products with the use of balanced crystalloids in obstetric hemorrhage | 2018 - 2019 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03434444 -
In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol
|
N/A | |
Terminated |
NCT01980173 -
Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care
|
N/A | |
Not yet recruiting |
NCT06033170 -
Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage
|
N/A | |
Not yet recruiting |
NCT02319707 -
Management of the Third Stage of Labor
|
Phase 3 | |
Completed |
NCT02163616 -
Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study
|
Phase 3 | |
Recruiting |
NCT01600612 -
Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial
|
N/A | |
Completed |
NCT02079558 -
Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section
|
Phase 2 | |
Withdrawn |
NCT01108302 -
Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT00097123 -
RCT of Misoprostol for Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT02883673 -
Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage
|
N/A | |
Completed |
NCT02542813 -
Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers
|
Phase 1 | |
Completed |
NCT04201665 -
EMG for Uterotonic Efficiency Estimation
|
N/A | |
Terminated |
NCT03246919 -
Ideal Time of Oxytocin Infusion During Cesarean Section
|
Phase 4 | |
Not yet recruiting |
NCT05501106 -
Reducing Postpartum Hemorrhage After Vaginal Delivery
|
N/A | |
Completed |
NCT05429580 -
Prophylactic Tranexamic Acid Use After Vaginal Delivery
|
N/A | |
Terminated |
NCT03064152 -
Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery
|
N/A | |
Recruiting |
NCT05382403 -
Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage
|
N/A | |
Not yet recruiting |
NCT02853552 -
Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding
|
Phase 4 | |
Completed |
NCT03344302 -
Oxytocin Administration During Cesarean Section
|
Phase 4 | |
Completed |
NCT02805426 -
Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage
|
Phase 4 |